Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study
Retrospective cohort study shows efgartigimod improves outcomes in myasthenic crisis compared to IVIg, suggesting a potential first-line role.
Key Points
Efgartigimod demonstrated significantly greater improvement in MG-ADL and QMG scores during weeks 2-4 compared to IVIg, indicating better clinical effectiveness.
By week 4, 90% of patients receiving efgartigimod achieved meaningful improvement in MG-ADL, compared to 57.1% in the IVIg group, highlighting its efficacy.
Retrospective cohort analysis involved 51 AChR-Ab+ patients, assessing clinical outcomes after treatment with either efgartigimod or IVIg over four weeks.
Efgartigimod showed reduced complications and a higher proportion of patients reaching minimal symptom expression, underscoring its safety profile.